Citius Pharmaceuticals Financials - Benzinga

Citius Pharmaceuticals Inc

CTXRNASDAQ

Trade with Public

Trade with Public

$0.7556

0.0223%

At close: Aug 14, 5:00 PM EST

$0.6801

-0.0755-9.99%

After Hours: Aug 14, 7:58 PM EST

Earnings: Q3 2026 Earnings were released on Fri Aug 14th, after the market close

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Citius Pharmaceuticals Financials

Citius Pharmaceuticals (CTXR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Citius Pharma Q3 EPS $(0.34) Beats $(0.36) Estimate, Sales $1.494M Miss $5.467M Estimate

Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.36) by 5.56 percent. This is a 57.5 percent increase over losses of $(0.80) per share from the

Benzinga Newsdesk

Citius Pharmaceuticals Q1 Earnings Report: What Investors Need to Know

Benzinga Insights

PRO
Citius Pharma Q1 EPS $(0.38) Misses $(0.30) Estimate, Sales $3.944M Beat $3.455M Estimate

Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.30) by 26.67 percent. This is a 70.77 percent increase over losses of $(1.30) per share from

Benzinga Newsdesk

Gold Edges Lower; Omeros Shares Jump

Avi Kapoor

Dow Gains Over 100 Points; US Jobless Claims Decline

Avi Kapoor

Stock Market Today: Dow Jones, Nasdaq Futures Slip On Christmas Eve Despite Strong Q3 GDP Report— UiPath, AST SpaceMobile, Ramaco In Focus (UPDATED)

(Editor’s note: The future prices of benchmark tracking ETFs and headline were updated in the story.) U.S. stock futures slipped on Wednesday after Tuesday’s higher close. Futures of major benchmark indices fell.

Rishabh Mishra